Hastings Gregory S, serving as Vice President of Animal Health at Neogen Corp, has reported recent stock transactions that may indicate his confidence in the company's prospects. The transactions involve both the acquisition and disposal of shares, reflecting ongoing activity in his role.
Background
Neogen Corp, identified by the Central Index Key 0000711377, operates within the in vitro and in vivo diagnostic substances industry. The company is incorporated in Michigan and has its fiscal year ending on May 31. Recent filings include a Form 4 and a Form 3, both submitted on October 23, 2026.
What the Filing Says
The filing, accession number 0000711377-26-000034, details two transactions involving Neogen's common stock. On October 14, 2026, Hastings acquired 287 shares at a price of $12 each, increasing his holdings to 32,655 shares. Additionally, he disposed of 80 shares, bringing his total ownership to 32,575 shares following these transactions.
Impact
This insider trading activity may influence perceptions among investors and analysts regarding Neogen's future performance. As a key officer in the company, Hastings' transactions could be seen as a signal of confidence in the company's direction.
What's Next
The filing does not say what happens next.
Details of the Transactions
In addition to the acquisition and disposal of common stock, the filing also reveals that Hastings Gregory S exercised 287 Restricted Stock Units (RSUs) on October 14, 2026. Each RSU is equivalent to one share of common stock, and the transaction was executed at a conversion price of $12 per share. Following this transaction, Hastings no longer held any RSUs, as they were fully settled for an equal number of shares of common stock.
Ownership Structure
After the reported transactions, Hastings Gregory S holds a total of 32,575 shares of Neogen Corp's common stock. This reflects his direct ownership, as the filing indicates that he does not hold any indirect ownership in the company.
Signature and Filing Information
The Form 4 was signed by Christopher Sefcheck, acting as attorney in fact for Hastings, on October 23, 2026. The filing was submitted under the 1934 Act and is associated with SEC file number 000-17988.
Additional Context
The filing does not provide information regarding Hastings' future plans or any potential strategic initiatives he may be involved in at Neogen Corp. Additionally, there are no details on how these transactions might align with the company's overall performance or future outlook.